PainReform announced the pricing of a public offering of an aggregate of 5,000,000 of the Company’s ordinary shares and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per share and accompanying warrant. The warrants will have an exercise price of $0.80 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about April 18, 2024, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be $4 million. The Company intends to use the net proceeds from this offering to advance the Company’s clinical studies, and for general corporate purposes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRFX:
- PainReform’s PRF-110 Sets New Pain Relief Benchmark
- PainReform says IVR rates of PRF-110 superior for post-surgical pain products
- PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
- PainReform Shareholders Approve Key Proposals
- PainReform Hits 50% Enrollment Milestone
